



Press release
Regulated information

Omega Pharma raises expected maximum of EUR 300 million with bond issue after first day

Large over-subscription

Nazareth (Belgium) - 26 April 2012 (7:00 p.m. CET). Omega Pharma announces that the public offer in Belgium and the Grand-Duchy of Luxembourg for two series of retail bonds has been closed in consultation with the Joint Lead Managers (ING Belgium, KBC Bank, Belfius Bank and BNP Paribas Fortis) after the first day of the subscription period because the combined expected total maximum amount of EUR 300 million was largely achieved.

The total issue amount is EUR 300 million of which EUR 180 million for the 5 year bond and EUR 120 million for the 7 year bond. The total amount of subscriptions received by the Joint Lead Managers is significantly higher than the total issue amount. Because of this over-subscription, subscriptions will be reduced proportionally. Investors will be informed about this via their financial intermediary.

More information about this public offer can be found in the corresponding prospectus of 23 April 2012, approved by the *Commission de Surveillance du Secteur Financier* (Luxembourg), which is available at the Joint Lead Managers as well as on the company's website: www.omega-pharma.be.

The bonds will be issued and accepted for trading on Luxembourg Stock Exchange on 23 May 2012.

Omega Pharma is an OTC healthcare company headquartered in Nazareth (Belgium) with operations in 35 countries across Europe and selected emerging markets. Its products are sold across an extensive network of pharmacies and related retail outlets.

(end)